Trade | Association for Accessible Medicines

Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs

WASHINGTON DC (February 25, 2019) – Jonathan Kimball joins the Association for Accessible Medicines as Vice President, Trade and International Affairs, effective today.

“Jonathan will bring a wealth of government and industry advocacy experience to an area of increasing importance to AAM and our members,” said Jeff Francer, AAM’s Senior Vice President and General Counsel. “We are extremely lucky to have him on our team.”

Read more about Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs

AAM Statement on Signing of USMCA by President

WASHINGTON, DC (November 30, 2018) – AAM is extremely concerned that the USMCA, if left in its current form, will decrease prescription drug competition, inevitably leading to increased drug prices in the United States. This will harm American patients, job creators, workers and taxpayers. Furthermore, several provisions within the agreement are inconsistent with U.S. law and, if left unchanged, could lead to inappropriate changes in U.S.

Read more about AAM Statement on Signing of USMCA by President

Poll Results: Americans’ Attitudes on U.S. Trade Policy and Drug Pricing

WASHINGTON DC (November 14, 2018) – Republican and Democratic voters agree. Americans do not want the new U.S.-Mexico-Canada trade agreement (USMCA) to raise drug prices or decrease competition from more affordable generic or biosimilar medicines.

Read more about Poll Results: Americans’ Attitudes on U.S. Trade Policy and Drug Pricing

Poll Results: USMCA Trade Agreement

Addressing the high cost of prescription drugs continues to be a top health care priority for the public. On October 1, the U.S. Trade Representative (USTR) announced a proposed agreement with Canada and Mexico to revise the North American Free Trade Agreement (NAFTA).

Read more about Poll Results: USMCA Trade Agreement

Generic and Biosimilars Approvals Are Only Half the Story

The U.S. Food and Drug Administration (FDA) plays a critical role in keeping Americans healthy. When it comes to drug approvals, the FDA’s scientists and regulators strive every day to keep pace with the most current advances in science so that patients can benefit from innovative, safe, and effective medicines.

Read more about Generic and Biosimilars Approvals Are Only Half the Story

Op-Ed: The New NAFTA Could Thwart President's Promise to Lower Prescription Drug Costs

President Trump has declared lowering our nation’s drug costs a high priority. But his renegotiated North American Free Trade Agreement, which has now been rebranded by Trump as the US-Mexico-Canada Agreement (USMCA), will actually prevent him from reducing the exorbitant costs of prescription drugs for America’s patients.

Read more about Op-Ed: The New NAFTA Could Thwart President's Promise to Lower Prescription Drug Costs

AAM Opposes Barriers to Generic Drug and Biosimilar Access in Proposed US-Mexico-Canada Agreement (USMCA)

WASHINGTON DC (October 1, 2018) – AAM is extremely concerned that the proposed US-Mexico-Canada trade agreement will provide a windfall for brand-name drug manufacturers and raise prescription drug prices for patients in the United States.

Read more about AAM Opposes Barriers to Generic Drug and Biosimilar Access in Proposed US-Mexico-Canada Agreement (USMCA)

Preserve Patient Access in NAFTA 2.0

The U.S. is actively negotiating with Mexico and Canada to revise the North American Free Trade Agreement (NAFTA). One of the provisions under discussion would increase brand-name drug exclusivity (i.e., monopolies) as part of a new trilateral agreement. Imposing additional brand-name drug exclusivity only keeps already high brand drug prices out of reach for patients for longer.

A recent poll shows that Americans oppose longer monopolies for big brand name pharmaceutical companies in NAFTA 2.0. View the results in the infographic below.

Read more about Preserve Patient Access in NAFTA 2.0

How a Renegotiated NAFTA Could Keep Drug Prices High for Patients

This fact sheet provides key takeaways and resources for lawmakers and was shared at the Capitol Hill briefing on September 14, 2018.

Read more about How a Renegotiated NAFTA Could Keep Drug Prices High for Patients

North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics

WASHINGTON DC (August 28, 2018) – Statement of the Association for Accessible Medicines, Canadian Generic Pharmaceutical Association, and Mexican Association of Generic Medicines on the Announcement U.S.-Mexico Understanding on Biologic Exclusivity

Read more about North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics